hotspot -WSS

hotspot

author：hotspot 2025-09-30 00:50:40 - browse：2565

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Pfizer is about to make a big push in cancer. Will investors listen?

knowledge

focus

WSS

Pediatric cancer treatments threatened by a new FDA policy

BIO selects John Crowley as new CEO

Despite FDA concern, risk that CAR

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Diagnostic tests are hitting their mathematical limits

NEJM study measures Covid brain fog, impact on IQ

focus

hotspot

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Mayo Clinic plans $5B tech

FDA approval of Sarepta Duchenne genetic therapy gives me hope

With clinical trial data readouts, here's how to spot spin

Affirmative action in medical school literally saved lives

Ohio train derailment: Experts on toxic chemical risks

Supreme Court strikes down use of affirmative action

J&J to emphasize cancer drugs, stop much of its vaccine research

What does generative AI mean for health care? We asked experts

Using force crossed my mind when examining a defiant young patient

focus

Ohio train derailment: Experts on toxic chemical risks

With clinical trial data readouts, here's how to spot spin

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Cigna, Humana reportedly in talks to merge

CDC director unscathed in first congressional testimony

Study fuels hope CAR

hotspot

knowledge

focus

focus